3SBio Inc (83B) - Total Liabilities
Based on the latest financial reports, 3SBio Inc (83B) has total liabilities worth €5.81 Billion EUR (≈ $6.80 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 3SBio Inc (83B) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
3SBio Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how 3SBio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 3SBio Inc (83B) total assets.
3SBio Inc Competitors by Total Liabilities
The table below lists competitors of 3SBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frontdoor Inc
NASDAQ:FTDR
|
USA | $1.90 Billion |
|
Rigetti Computing Inc
NASDAQ:RGTI
|
USA | $110.80 Million |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
USA | $56.25 Million |
|
Jiangsu Boqian New Materials Stock Co Ltd
SHG:605376
|
China | CN¥333.09 Million |
|
United Plantations Bhd
KLSE:2089
|
Malaysia | RM548.41 Million |
|
Dropbox Inc
NASDAQ:DBX
|
USA | $4.71 Billion |
|
Scout24 AG
XETRA:G24
|
Germany | €1.08 Billion |
|
AAK AB
ST:AAK
|
Sweden | Skr12.65 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down 3SBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 83B net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 3SBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 3SBio Inc (2016–2025)
The table below shows the annual total liabilities of 3SBio Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.81 Billion ≈ $6.80 Billion |
-5.86% |
| 2024-12-31 | €6.18 Billion ≈ $7.22 Billion |
-13.15% |
| 2023-12-31 | €7.11 Billion ≈ $8.31 Billion |
+7.94% |
| 2022-12-31 | €6.59 Billion ≈ $7.70 Billion |
+44.64% |
| 2021-12-31 | €4.55 Billion ≈ $5.33 Billion |
-0.66% |
| 2020-12-31 | €4.58 Billion ≈ $5.36 Billion |
+3.03% |
| 2019-12-31 | €4.45 Billion ≈ $5.20 Billion |
-9.78% |
| 2018-12-31 | €4.93 Billion ≈ $5.77 Billion |
-19.45% |
| 2017-12-31 | €6.12 Billion ≈ $7.16 Billion |
+43.32% |
| 2016-12-31 | €4.27 Billion ≈ $4.99 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more